8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T26889 | Borofalan(10B) | L-4-Boronophenylalanine | Others |
Borofalan(10B) (L-4-Boronophenylalanine) echibits antineoplastic effects. Borofalan can be used in studies on recurrent or locally advanced head and neck cancer. | |||
T2618 | LGK974 | LGK 974,LGK-974,NVP-LGK974,WNT974 | Porcupine |
LGK974 (NVP-LGK974) is an effective and selective PORCN inhibitor and inhibits Wnt signaling (IC50: 0.4 nM) in TM3 cells. It has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cel... | |||
T76890 | Petosemtamab | MCLA 158 | EGFR |
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab... | |||
T77423 | Lirilumab | ONO-4483,IPH2102 | Virus Protease |
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-depende... | |||
T21119 | Cevimeline | AF-102B,FKS 508,SNI 2011,HSDB 7286 | |
Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase saliv... | |||
T68661 | Edatrexate | CGP 30694 | |
Edatrexate (CGP 30694), also known as 10-Ethyl-10-deazaaminopterin, is an analog of Methotrexate that demonstrates antitumor activity against Methotrexate-resistant tumors. This antifolate antimetabolite is utilized in r... | |||
T63556 | EGFR-IN-59 | ||
EGFR-IN-59 is an EGFR inhibitor with an IC50 value of 190 nM and an all-time apoptosis inducer. EGFR-IN-59 exhibited cytotoxicity against a non-small lung cancer cell line (A549) and normal lung fibroblasts (WI38) with I... | |||
T72776 | NR2F1 agonist 1 | ||
NR2F1 agonist 1, a specific nuclear receptor NR2F1 activator, initiates dormancy programs in cancer cells by upregulating NR2F1 and its target genes controlling dormancy. This compound promotes neural crest-like features... |